Kamran MAHMUTYAZICIOĞLU, Fahri Halit BEŞİR, Mustafa BARDAKÇI

Hormone replacement therapy-related changes in the early postmenopausal period (critical window): an in vivo brain proton magnetic resonance spectroscopy study

Findings from clinical studies in postmenopausal women with late initiation of hormone replacement therapy (HRT) that test whether HRT protects cognitive functions in women are inconsistent. The aim of this study was to investigate the effects of HRT on brain metabolite ratios when initiated in the early postmenopausal period (critical window). Materials and methods: Proton magnetic resonance spectrometry (1H MRS) was performed in 4 brain regions of 47 healthy postmenopausal women (21 received HRT, 26 did not). The subjects were aged between 45 and 65 years. The duration of HRT ranged from 1 to 12 years (mean: 6.3 years). The duration of menopause was 2-12 years (mean: 6.1 years) for HRT users and 1-20 years (mean: 7.8 years) for non-HRT users. Metabolite ratios [N-acetyl aspartate/choline (NAA/Cho), NAA/creatine (Cr), and Cho/Cr] were evaluated. Results: Cho/Cr ratios were significantly increased and NAA/Cho ratios significantly decreased in all 4 regions in the HRT user group compared to the other group after elimination of the effects of age and menopause duration. Regression analysis revealed an association only between NAA/Cho and duration of menopause. Conclusion: HRT-related changes in metabolite ratios are found in all brain regions. Decreased NAA/Cho and increased Cho/Cr levels do not support the neuroprotective role of HRT in the critical window.

Anahtar Kelimeler:

Menopause, hormone replacement therapy, critical window, proton MR spectroscopy, metabolite ratios

Hormone replacement therapy-related changes in the early postmenopausal period (critical window): an in vivo brain proton magnetic resonance spectroscopy study

Keywords:

Menopause, hormone replacement therapy, critical window, proton MR spectroscopy, metabolite ratios,

PDF

___

Taylor HS, Manson JE. Update in hormone therapy use in menopause. J Clin Endocrinol Metab 2011; 96: 255–64.
Tiidus PM. Benefits of estrogen replacement for skeletal muscle mass and function in post-menopausal females: evidence from human and animal studies. EAJM 2011; 43: 109–14.
Malatyalıoğlu E, Kökçü A, Yanık FF, Alper T. Effects of four different hormone replacement therapy regimens on certain cardiovascular risk factors. Turk J Med Sci 2000; 30: 469–73.
Sherwin BB. Hormones, mood and cognitive functioning in postmenopausal woman. Obstet Gynecol 1996; 87: 20–6.
Thakur MK, Sharma PK. Aging of brain: role of estrogen. Neurochem Res 2006; 31: 1389–98.
Pompili A, Arnone B, Gasbarri A. Estrogens and memory in physiological and neuropathological conditions. Psychoneuroendocrinology 2012; 37: 1379–96.
Sherwin BB, Henry JF. Brain aging modulates the neuroprotective effects of estrogen on selective aspects of cognition in women: a critical review. Front Neuroendocrinol 2008; 29: 88–113.
Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN 3rd, Assaf AR, Jackson RD et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289: 2651–62.
Resnick SM, Henderson VW. Hormone therapy and risk of Alzheimer disease: a critical time. JAMA; 2002: 288: 2170–2.
Maki PM. Hormone therapy and cognitive function: is there a critical period for benefit? Neuroscience 2006; 138: 1027–30.
Loucks TL, Berga SL. Does postmenopausal estrogen use confer neuroprotection? Semin Reprod Med 2009; 27: 260–74.
Maki PM, Dumas J. Mechanisms of action of estrogen in the brain: insights from human neuroimaging and psychopharmacologic studies. Semin Reprod Med 2009; 27: 250–9.
Mahmutyazıcıoğlu K, Konuk N, Özdemir H, Atasoy N, Atik L, Gündoğdu S. Evaluation of the hippocampus and the anterior cingulate gyrus by proton MR spectroscopy in patients with post-traumatic stress disorder. Diagn Interv Radiol 2005; 11: 125–9.
McEwen B. Estrogen action throughout the brain. Recent Prog Horm Res 2002; 57: 357–84.
Brann DW, Dhandapani K, Wakade C, Mahesh VB, Khan MM. Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications. Steroids 2007; 72: 381–405.
Low LF, Anstey KJ. Hormone replacement therapy and cognitive performance in postmenopausal women—review by cognitive domain. Neurosci Biobehav Rev 2006; 30: 66–84.
Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA 2004; 291: 2947–58.
Coker LH, Espeland MA, Rapp SR, Legault C, Resnick SM, Hogan P, Gaussoin S, Dailey M, Shumaker SA. Postmenopausal hormone therapy and cognitive outcomes: the Women’s Health Initiative Memory Study (WHIMS). J Steroid Biochem Mol Biol 2010; 118: 304–10.
Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, Bacal C, Lingle DD, Metter E. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer’s disease. The Baltimore Longitudinal Study of Aging. Neurology 1997; 48: 1517–21.
Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, Breitner JC. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 2002; 288: 2123–9.
Boccardi M, Ghidoni R, Govoni S, Testa C, Benussi L, Bonetti M, Binetti G, Frisoni GB. Effects of hormone therapy on brain morphology of healthy postmenopausal women: a voxel-based morphometry study. Menopause 2006; 13: 584–91.
Erickson KI, Colcombe SJ, Raz N, Korol DL, Scalf P, Webb A, Cohen NJ, McAuley E, Kramer AF. Selective sparing of brain tissue in postmenopausal women receiving hormone replacement therapy. Neurobiol Aging 2005; 26: 1205–13.
Lord C, Buss C, Lupien SJ, Pruessner JC. Hippocampal volumes are larger in postmenopausal women using estrogen therapy compared to past users, never users and men: a possible window of opportunity effect. Neurobiol Aging 2008; 29: 95–101.
Low LF, Anstey KJ, Maller J, Kumar R, Wen W, Lux O, Salonikas C, Naidoo D, Sachdev P. Hormone replacement therapy, brain volumes and white matter in postmenopausal women aged 60–64 years. Neuroreport 2006; 17: 101–4.
Raz N, Rodrigue KM, Kennedy KM, Acker JD. Hormone replacement therapy and age-related brain shrinkage: regional effects. Neuroreport 2004; 15: 2531–4.
den Heijer T, Geerlings MI, Hofman A, de Jong FH, Launer LJ, Pols HA, Breteler MM. Higher estrogen levels are not associated with larger hippocampi and better memory performance. Arch Neurol 2003; 60: 213–20.
Resnick SM, Espeland MA, Jaramillo SA, Hirsch C, Stefanick ML, Murray AM, Ockene J, Davatzikos C. Postmenopausal hormone therapy and regional brain volumes: the WHIMS- MRI study. Neurology 2009; 72: 135–42.
Sherwin BB. Estrogen and cognitive aging in women. Neuroscience 2006; 138: 1021–6.
Whitmer RA, Quesenberry CP, Zhou J, Yaffe K. Timing of hormone therapy and dementia: the critical window theory revisited. Ann Neurol 2011; 69: 163–9.
Jezierski MK, Sohrabji F. Neurotrophin expression in the reproductively senescent forebrain is refractory to estrogen stimulation. Neurobiol Aging 2001; 22: 309–19.
Gibbs RB. Effects of gonadal hormone replacement on measures of basal forebrain cholinergic function. Neuroscience 2000; 101: 931–8.
Erickson KI, Voss MW, Prakash RS, Chaddock L. Kramer AF. A cross-sectional study of hormone treatment and hippocampal volume in postmenopausal women: evidence for a limited window of opportunity. Neuropsychology 2010; 24: 68–76.
Martin WR. MR spectroscopy in neurodegenerative disease. Mol Imaging Biol 2007; 9: 196–203.
Ross AJ, Sachdev PS. Magnetic resonance spectroscopy in cognitive research. Brain Res Brain Res Rev 2004: 44: 83–102.
Schuff N, Meyerhoff DJ, Mueller S, Chao L, Sacrey DT, Laxer K, Weiner MW. N-Acetylaspartate as a marker of neuronal injury in neurodegenerative disease. Adv Exp Med Biol 2006; 576: 241–62.
Ruiz-Cabello J, Cohen JS. Phospholipid metabolites as indicators of cancer cell function. NMR Biomed 1992; 5: 226–
Chang L, Ernst T, Tornatore C, Aronow H, Melchor R, Walot I, Singer E, Cornford M. Metabolite abnormalities in progressive multifocal leucoencephalopathy by proton magnetic resonance spectroscopy. Neurology 1997; 48: 836–45.
Sartorius A, Vollmayr B, Neumann-Haefelin C, Ende G, Hoehn M, Henn FA. Specific creatine rise in learned helplessness induced by electroconvulsive shock treatment. Neuroreport 2003; 14: 2199–201.
Robertson DM, van Amelsvoort T, Daly E, Simmons A, Whitehead M, Morris RG, Murphy KC, Murphy DG. Effects of estrogen replacement therapy on human brain aging: an in vivo 1H MRS study. Neurology 2001; 57: 2114–7.
Craig MC, Daly EM, O’Gorman R, Rymer J, Lythgoe D, Ng G, Simmons A, Maki PM, Murphy DG. Effects of acute ovarian hormone suppression on the human brain: an in vivo 1H MRS study. Psychoneuroendocrinology 2007; 32: 1128–32.
Hu L, Yue Y, Zuo PP, Jin ZY, Feng F, You H, Li ML, Ge QS. Evaluation of neuroprotective effects of long-term low dose hormone replacement therapy on postmenopausal women brain hippocampus using magnetic resonance scanner. Chin Med Sci J 2006; 21: 214–8.
Genazzani AR, Pluchino N, Bernardi F, Centofanti M, Luisi M. Beneficial effect of tibolone on mood, cognition, well-being, and sexuality in menopausal women. Neuropsychiatr Dis Treat 2006; 2: 299–307.
Kenemans P, Speroff L. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 2005; 51: 21–8.
Biglia N, Maffei S, Lello S, Nappi RE. Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials. Gynecol Endocrinol 2010; 26: 804–14.
Yasui T, Matsui S, Tani A, Kunimi K, Yamamoto S, Irahara M. Androgen in postmenopausal women. J Med Invest 2012; 59: 12–27.
Hogervorst E, Boshuisen M, Riedel W, Willeken C, Jolles J. The effect of hormone replacement therapy on cognitive function in elderly women. Psychoneuroendocrinology 1999; 24: 43–68.
Woolley CS, McEwen BS. Roles of estradiol and progesterone in regulation of hippocampal dendritic spine density during the estrous cycle in the rat. J Comp Neurol 1993; 8: 293–306.
Kampen DL, Sherwin BB. Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol 1994; 83: 979–83.
Limouzin-Lamothe MA, Mairon N, Joyce CR, Le Gal M. Quality of life after the menopause: influence of hormonal replacement therapy. Am J Obstet Gynecol 1994; 170: 618–24.
Genazzani AR, Pluchino N, Bernardi F, Centofanti M, Luisi M. Beneficial effect of tibolone on mood, cognition, well-being, and sexuality in menopausal women. Neuropsychiatr Dis Treat 2006; 2: 299–307.
Pfefferbaum A, Adalsteinsson E, Spielman D, Sullivan EV, Lim KO. In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain grey matter and white matter: effects of normal aging. Magn Reson Med 1999; 41: 276–84.
Kadota T, Horinouchi T, Kuroda C. Development and aging of the cerebrum: assessment with proton MR spectroscopy. Am J Neuroradiol 2001; 22: 128–35.